After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Vertex Pharmaceuticals Incorporated (VRTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.54, or -0.16%, to $346.01. The Vertex Pharmaceuticals Incorporated has recorded 51,878 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13.
VRTX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $346.55 and fluctuated between $348.99 as its day high and $345.41 as its day low. The current market capitalization of Vertex Pharmaceuticals Incorporated is $89.68B. A total of 0.64 million shares were traded on the day, compared to an average of 1.08M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, VRTX has seen 2 BUY and 7 SELL insider trades, representing the acquisition of 19,853 and the disposition of 27,986 shares. Over the last 12 months, there were 50 BUYs and 217 SELLs from insiders. Insiders purchased 454,389 shares during that period but sold 346,378.
In the most recent transaction, Bozic Carmen sold 5,651 shares of VRTX for 352.66 per share on Sep 05. After the transaction, the EVP and CMO now owns 57,556 company shares. In a previous transaction on Aug 23, Tatsis Ourania sold 2,500 shares at 355.00 per share. VRTX shares that EVP, Chief Reg. & Quality Off. owns now total 48,637.
Among the insiders who sold shares, Sachdev Amit disposed of 10,031 shares on Aug 10 at a per-share price of $350.00. This resulted in the EVP, Chief Patient Officer holding 58,814 shares of VRTX after the transaction. In another insider transaction, Kearney Terrence C sold 10,000 shares at $350.00 per share on Aug 10. Company shares held by the Director now total 6,536.
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. VRTX’s most recent ex-dividend date was when it declared a $0.40 quarterly dividend that was paid in cash on 3/13/2013.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for VRTX in the last 3 months, the mean price target is $386.81 with high estimates of $456.00 and low estimates of $315.00. In terms of 52-week highs and lows, VRTX has a high of $367.00 and a low of $276.57.
As of this writing, VRTX has an earnings estimate of $3.97 per share for the current quarter. EPS was calculated based on a consensus of 22 estimates, with a high estimate of $4.39 per share and a lower estimate of $3.34. The company reported an EPS of $3.05 in the last quarter, which was 1.70% higher than expectations of $3.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $556.70M in debt and $1.87B in liabilities at the time. Its Book Value Per Share was $60.03, while its Total Shareholder’s Equity was $10.10B.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.42.